KIRSCH ARTHUR S 4

What Happened Arthur S. Kirsch, a director of Atea Pharmaceuticals, was granted two restricted stock unit (RSU) awards on June 18, 2026 (transaction code A). The awards total 64,400 RSUs (26,700 RSUs + 37,700 RSUs) listed at $0.00 per unit (no cash paid at grant). These are derivative awards that represent the contingent right to receive one share of Atea common stock per RSU upon vesting. This is a compensation grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-18 (filed on 2026-06-23).
• Grants: 26,700 RSUs and 37,700 RSUs; total = 64,400 RSUs; grant price reported $0.00 (derivative award).
• Vesting (footnote): Each RSU converts to one share upon vesting. RSUs vest in a single installment on the earlier of (i) the next annual meeting after 6/18/2026 or (ii) 6/18/2027, subject to Kirsch’s continued service (Footnotes F1–F2).
• Footnote F3 references an option vesting schedule, but no option exercise/option grant is reported in these transactions.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Timeliness: Form 4 was filed 5 days after the grant (filed 6/23/2026 for a 6/18/2026 transaction); Form 4s are normally due within 2 business days, so this filing appears late.

Context RSU grants are a common form of executive/director compensation and are typically intended for retention; they do not require an immediate cash outlay and only convert to shares if the vesting conditions are met. Because this is a grant (compensation), it should be viewed differently from open-market purchases or sales and does not, by itself, indicate the insider’s trading sentiment.